Clarity Pharmaceuticals (ASX:CU6) Treats First Patient in Phase II SECuRE Trial
Trial Progress
Clarity Pharmaceuticals has treated the first of 24 planned participants in the Cohort Expansion Phase II of the SECuRE trial with an 8 GBq dose of 67Cu-SAR-bisPSMA, following the Safety Review Committee’s approval to increase the dose and number of cycles.
Product Formulation
The company introduced an improved formulation of 67Cu-SAR-bisPSMA, offering room temperature stability and scalability, essential for late-stage clinical trials and commercial manufacture.
Executive Comments
Dr Alan Taylor, Executive Chairperson, stated, “We are incredibly excited about the progress we’ve achieved in the SECuRE trial to date and look forward to continuing to generate promising data in the Cohort Expansion Phase. With the latest protocol amendments ensuring that we are utilising the most recent advances and knowledge in the radiopharmaceutical space, we continue to be driven by the highest standards of clinical trial management and research.”
Motley Fool contributor Abbie Stokes has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
This article was generated using GPT-4o mini, a Large Language Model (LLM), to generate summaries of investing news. While AI is generating the content, we know better than to blindly trust our future robot overlords, and every article is edited and fact-checked by an editor holding the appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content of everything published by The Capital Club.